Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
Children's Hospital of Philadelphia
Taiho Oncology, Inc.
Massachusetts General Hospital
Ossium Health, Inc.
Cullgen (Shanghai),Inc
Medical University of Gdansk
Ohio State University Comprehensive Cancer Center
Peter MacCallum Cancer Centre, Australia
Children's Hospital of Philadelphia
University of Texas Southwestern Medical Center
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
City of Hope Medical Center
Medical College of Wisconsin
Universitaire Ziekenhuizen KU Leuven
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
University of Nebraska
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
University of Alabama at Birmingham
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Baylor College of Medicine
Brown University
Roswell Park Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
PrECOG, LLC.
CTI BioPharma
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Indonesia University
Boston Children's Hospital
University College, London
University of Maryland, Baltimore
University of Maryland, Baltimore
Novartis
University of Arizona
Dana-Farber Cancer Institute
Columbia University
University of Washington